PTPRC and hematopoietic and lymphoid cell neoplasm: In addition, in this second phase, the LymphoclonalTM tube was replaced by LST, which included both CD45 and CD56 for improved distinction between hematopoietic and non-hematopoietic tumors and, e.g., CD4, CD8, anti-Igκλ, and CD38 for more accurate B, T, and NK cell subsetting (Table 2).